DDInter1802 DDInter808
Ticagrelor, or AZD6140, was first described in the literature in 2003.[A204170,A2903] Ticagrelor is an ADP derivative developed for its P2Y<sub>12</sub> receptor antagonism. Unlike [clopidogrel], ticagrelor is not a prodrug. It is marketed by Astra Zeneca as Brilinta in the US and Brilique or Possia in the EU,. Ticagrelor was granted EMA approval on 3 December 2010. Ticagrelor was granted FDA approval on 20 July 2011.
Garlic allergenic extract is used in allergenic testing.
Ticagrelor {u} (Compound) treats {v} (Disease) coronary artery disease
Ticagrelor {u} (Compound) binds {v} (Gene) ABCB1
Ticagrelor {u} (Compound) is included by {v} (Pharmacologic Class) Phenylalanine Hydroxylase Activators
Ticagrelor {u} (Compound) causes {v} (Side Effect) Unspecified disorder of skin and subcutaneous tissue
Ticagrelor {u} may cause a minor interaction that can limit clinical effects when taken with {v} Clove
Ticagrelor {u} may cause a minor interaction that can limit clinical effects when taken with {v} Nifedipine
Ticagrelor {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lepirudin
Ticagrelor {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Vemurafenib
Ticagrelor {u} may lead to a major life threatening interaction when taken with {v} Indinavir
Ticagrelor {u} may lead to a major life threatening interaction when taken with {v} Relugolix
Ticagrelor (Compound) treats coronary artery disease (Disease)
Ticagrelor (Compound) binds ABCB1 (Gene)
Ticagrelor (Compound) is included by Phenylalanine Hydroxylase Activators (Pharmacologic Class)
Ticagrelor (Compound) causes Unspecified disorder of skin and subcutaneous tissue (Side Effect)
Ticagrelor may cause a minor interaction that can limit clinical effects when taken with Clove
Ticagrelor may cause a minor interaction that can limit clinical effects when taken with Nifedipine
Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Lepirudin
Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Vemurafenib
Ticagrelor may lead to a major life threatening interaction when taken with Indinavir
Ticagrelor may lead to a major life threatening interaction when taken with Relugolix